DBV Technologies SA - American (DBVT) AI Stock Analysis

• Market Cap: $857.17M
• Dividend Yield: N/A
• Average Volume (3M): 557.77K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.12
• Revenue Growth: N/A
• EPS Growth: 1.29%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 40,155,544
• 10 Day Avg. Volume: 375,581
• 30 Day Avg. Volume: 557,773
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 0.21
• Enterprise Value/Revenue: 350.36
• Enterprise Value/Gross Profit: -13.91
• Enterprise Value/Ebitda: -1.54
• 1Y Price Target: $46.40
• Price Target Upside: 123.29% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.4
• Revenue Forecast (FY): $3.96M

• Rating: 60 Neutral
• Price Target: $18.00 ▼(-13.38% Downside)

The score is held back primarily by very weak financial performance (minimal/declining revenue, large losses, and heavy ongoing cash burn implying financing risk). Offsetting this are strong clinical/corporate-event momentum from positive Phase 3 results with a planned BLA submission, and supportive technical trends with the stock trading above key moving averages.

Positive Factors

Innovative Technology

The proprietary Viaskin technology offers a unique approach to allergy treatment, potentially providing a competitive advantage in the biotechnology sector.

Low Leverage

Low leverage indicates financial prudence, allowing for greater flexibility in funding operations and strategic initiatives without excessive debt burden.

Partnership Opportunities

Partnerships with pharmaceutical firms can provide crucial funding and accelerate product development, enhancing long-term growth prospects.

Negative Factors

Revenue Decline

Significant revenue contraction indicates challenges in product sales and market penetration, potentially impacting future growth and sustainability.

Negative Cash Flow

Negative cash flow highlights liquidity challenges, limiting the company's ability to invest in R&D and operational expansion without external financing.

Persistent Losses

Ongoing losses suggest inefficiencies and high operational costs, which could hinder profitability and require strategic restructuring to improve margins.

DBV Technologies SA - American Business Overview & Revenue Model

Company Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

How the Company Makes Money

DBV Technologies generates revenue primarily through the development and commercialization of its therapeutic products, particularly those that leverage its Viaskin technology for treating food allergies. The company may receive funding through partnerships with other pharmaceutical firms for co-development agreements, licensing deals, or joint ventures that provide upfront payments, milestone payments, and royalties on sales. Additionally, DBV Technologies may obtain revenue through government grants and research funding aimed at supporting the development of its innovative therapies. The company's earnings are significantly influenced by the successful progression of its clinical trials and the eventual commercialization of its products.

DBV Technologies SA - American Financial Statement Overview

Summary

DBV Technologies SA faces financial instability with declining revenues and persistent losses. Despite low leverage, negative returns and cash flow issues present significant challenges. The company needs to address its revenue contraction and improve operational efficiency to stabilize its financial position.

Income Statement

DBV Technologies SA has experienced a significant decline in revenue from $15.73 million in the previous year to $2.57 million in the TTM (Trailing-Twelve-Months), indicating a revenue contraction. The company also posted negative EBIT and net income margins, reflecting ongoing operational challenges and high expenses relative to revenue. Despite gross profit being positive, the net profit margin remains negative.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, indicating limited leverage which is a positive aspect. However, the return on equity is negative due to the net losses, and the equity ratio has declined, indicating reduced financial stability. This suggests potential challenges in maintaining equity levels without external financing.

Cash Flow

DBV Technologies SA reported a negative free cash flow, with a deterioration in operating cash flow compared to the previous year. The free cash flow to net income ratio is negative, indicating cash flow issues. Despite a slight improvement in financing cash flow, the overall cash flow situation points to liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	511.00K	0.00	15.73M	4.80M	5.71M	11.28M
Gross Profit	-12.87M	-6.81M	15.73M	-15.50M	-3.56M	11.28M
EBITDA	-116.13M	-110.99M	-63.27M	-76.68M	-91.16M	-124.83M
Net Income	-125.53M	-113.72M	-72.73M	-96.30M	-97.81M	-159.56M
Balance Sheet
Total Assets	110.50M	65.66M	182.99M	246.52M	146.32M	272.25M
Cash, Cash Equivalents and Short-Term Investments	69.84M	32.46M	141.37M	209.19M	77.30M	196.35M
Total Debt	0.00	7.80M	6.55M	4.15M	10.66M	15.47M
Total Liabilities	57.64M	38.27M	42.80M	52.06M	47.29M	66.75M
Stockholders Equity	52.85M	27.39M	140.19M	194.45M	99.03M	205.49M
Cash Flow
Free Cash Flow	-98.29M	-106.81M	-80.33M	-56.45M	-109.16M	-168.42M
Operating Cash Flow	-98.26M	-104.47M	-79.65M	-55.70M	-108.24M	-165.61M
Investing Cash Flow	139.00K	-757.00K	-808.00K	-100.00K	-433.00K	-2.87M
Financing Cash Flow	117.80M	587.00K	6.77M	194.10M	274.00K	149.55M

DBV Technologies SA - American Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Positive. The current price of 20.78 is above the 20-day moving average (MA) of 18.81, above the 50-day MA of 16.47, and above the 200-day MA of 11.81, indicating a bullish trend. The MACD of 0.40 indicates Positive momentum. The RSI at 62.08 is Neutral, neither overbought nor oversold. The STOCH value of 65.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBVT.

DBV Technologies SA - American Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DBVT	60 Neutral	$857.17M	-3.96	-234.58%	―	―	1.29%
LXEO	58 Neutral	$547.40M	―	-80.69%	―	―	4.97%
PRTC	55 Neutral	$439.97M	10.55	14.55%	―	1268.81%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FDMT	47 Neutral	$431.37M	-1.92	-45.38%	―	―	―
LRMR	45 Neutral	$267.90M	-1.62	-78.24%	―	―	-67.41%
KRRO	42 Neutral	$82.68M	-0.93	-63.46%	―	―	21.61%

DBV Technologies SA - American Corporate Events

DBV Technologies Reports Positive Phase 3 Trial Results

On December 16, 2025, DBV Technologies announced positive topline results from its Phase 3 VITESSE trial of the VIASKIN® Peanut Patch for treating peanut-allergic children aged 4 to 7 years. The trial met its primary endpoint, showing a statistically significant treatment effect, with 46.6% of children in the treatment group meeting the response criteria compared to 14.8% in the placebo group. The safety profile was consistent with previous studies, and the company plans to submit a Biologics License Application in the first half of 2026. This milestone triggers the acceleration of the exercise period for certain warrants, reflecting a significant advancement in DBV’s mission to provide a well-tolerated, non-invasive treatment option for peanut allergies.

The most recent analyst rating on (DBVT) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.

DBV Technologies Appoints Dr. Philina Lee to Board

On October 30, 2025, DBV Technologies announced the appointment of Dr. Philina Lee to its Board of Directors, filling the vacancy left by Daniel Soland. Dr. Lee, who brings extensive experience from her previous roles at Blueprint Medicines and Fusion Pharmaceuticals, will also serve on the Compensation Committee. Her appointment, subject to shareholder approval, is expected to enhance DBV’s strategic direction as the company advances its VIASKIN® Peanut program for children with peanut allergies.

The most recent analyst rating on (DBVT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.